Pliant Therapeutics to Participate in Needham Healthcare Conference

Rhea-AI Summary

Pliant Therapeutics (Nasdaq: PLRX), a clinical-stage biotechnology company, will have its CEO, Bernard Coulie, participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 2:15 p.m. ET. The event can be accessed via the Investor Relations’ Events & Presentation page on Pliant’s website, with an audio archive available for 30 days. Pliant focuses on developing therapies for fibrosis, with its lead candidate, PLN-74809, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received Orphan Drug Designation from the FDA.

SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in a fireside chat as part of the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022, at 2:15 p.m. ET.

Interested parties can access the fireside chat from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations with an audio archive available for 30 days from the time they are made available.

About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of α_vß₆ and α_vß₁ integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of α_vß₁ for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit www.pliantrx.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Investor and Media Contact:

Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com

FAQ

When is Pliant Therapeutics participating in the Needham Virtual Healthcare Conference?

Pliant Therapeutics will participate in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 2:15 p.m. ET.

Who will represent Pliant Therapeutics at the conference?

Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will represent the company.

What is Pliant Therapeutics' lead product candidate?

Pliant Therapeutics' lead product candidate is PLN-74809, which is in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

What is the significance of PLN-74809?

PLN-74809 has received Orphan Drug Designation from the U.S. FDA for both idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

How can I access the fireside chat?

The fireside chat can be accessed from Pliant's Investor Relations’ Events & Presentation page on their website.